Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata

BACKGROUND. Alopecia areata (AA) is a common autoimmune disease with a lifetime risk of 1.7%; there are no FDA-approved treatments for AA. We previously identified a dominant IFN-γ transcriptional signature in cytotoxic T lymphocytes (CTLs) in human and mouse AA skin and showed that treatment with J...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:JCI Insight
Autores principales: Mackay-Wiggan, Julian, Jabbari, Ali, Nguyen, Nhan, Cerise, Jane E., Clark, Charlotte, Ulerio, Grace, Furniss, Megan, Vaughan, Roger, Christiano, Angela M., Clynes, Raphael
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society for Clinical Investigation 2016
Materias:
Clinical Medicine
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5033756/
https://ncbi.nlm.nih.gov/pubmed/27699253
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.89790
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares